Lisa Munakata
Overview
Explore the profile of Lisa Munakata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Omata D, Kawahara E, Munakata L, Tanaka H, Akita H, Yoshioka Y, et al.
Mol Pharm
. 2024 Sep;
21(11):5672-5680.
PMID: 39324825
Lipid nanoparticle-encapsulated mRNA (mRNA-LNP) vaccines have been approved for use to combat coronavirus disease 2019 (COVID-19). The mRNA-LNPs contain PEG-conjugated lipids. Clinical studies have reported that mRNA-LNPs induce the production...
2.
Kawai A, Noda M, Hirata H, Munakata L, Matsuda T, Omata D, et al.
ACS Nano
. 2024 Jun;
18(26):16589-16609.
PMID: 38885198
Adjuvants are effective tools to enhance vaccine efficacy and control the type of immune responses such as antibody and T helper 1 (Th1)- or Th2-type responses. Several studies suggest that...
3.
Hirakata M, Tomikawa E, Sakai C, Uchida M, Okano T, Shimozono R, et al.
Toxicol Appl Pharmacol
. 2024 Mar;
485:116912.
PMID: 38521368
Anthracycline anti-cancer drugs have been widely used in the treatment of several cancers; however, their use is limited by adverse effects (AEs). Alopecia is a common AE that is minimally...
4.
Hagiwara F, Omata D, Munakata L, Kageyama S, Maruyama K, Kudo N, et al.
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004464
Glioblastoma is a highly invasive and fatal disease. Temozolomide, a blood-brain barrier (BBB)-penetrant therapeutic agent currently used for glioblastoma, does not exhibit sufficient therapeutic effect. Cisplatin (CDDP), a versatile anticancer...
5.
Suzuki Y, Munakata L, Omata D, Koizumi K, Suzuki R
Immunotherapy
. 2023 Jan;
14(18):1443-1455.
PMID: 36597713
The feasibility of using nanoparticles derived from extract (Glycyrrhiza NPs) as a vaccine adjuvant for cancer immunotherapy was evaluated. C57BL/6J mice were immunized with ovalbumin (OVA) and Glycyrrhiza NPs. After...
6.
Omata D, Munakata L, Maruyama K, Suzuki R
J Med Ultrason (2001)
. 2022 Apr;
PMID: 35403931
Ultrasound induces the oscillation and collapse of microbubbles such as those of an ultrasound contrast agent, where these behaviors generate mechanical and thermal effects on cells and tissues. These, in...
7.
Omata D, Munakata L, Maruyama K, Suzuki R
Biol Pharm Bull
. 2021 Oct;
44(10):1391-1398.
PMID: 34602547
Ultrasound and microbubbles, an ultrasound contrast agent, have recently increased attention to developing novel drug delivery systems. Ultrasound exposure can induce mechanical effects derived from microbubbles behaviors such as an...
8.
Haseda Y, Munakata L, Kimura C, Kinugasa-Katayama Y, Mori Y, Suzuki R, et al.
PLoS One
. 2021 Aug;
16(8):e0254628.
PMID: 34339430
Most current clinical vaccines work primarily by inducing the production of neutralizing antibodies against pathogens. Vaccine adjuvants that efficiently induce T cell responses to protein antigens need to be developed....
9.
Omata D, Munakata L, Kageyama S, Suzuki Y, Maruyama T, Shima T, et al.
J Drug Target
. 2021 Jul;
30(2):200-207.
PMID: 34254554
Gene therapy is a promising technology for genetic and intractable diseases. Drug delivery carriers or systems for genes and nucleic acids have been studied to improve transfection efficiency and achieve...
10.
Maruyama T, Sugii M, Omata D, Unga J, Shima T, Munakata L, et al.
Int J Pharm
. 2020 Sep;
590:119886.
PMID: 32998031
Diagnostic ultrasound is non-invasive and provides real-time imaging. Microbubbles (MBs) are ultrasound contrast agents used to observe small blood flow, such as tumor tissue. However, MBs have short blood flow...